Francis Parnis
About
Francis Parnis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Francis Parnis has authored 60 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Francis Parnis's work include Prostate Cancer Treatment and Research (23 papers), Renal cell carcinoma treatment (14 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Francis Parnis is often cited by papers focused on Prostate Cancer Treatment and Research (23 papers), Renal cell carcinoma treatment (14 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Francis Parnis collaborates with scholars based in Australia, United States and United Kingdom. Francis Parnis's co-authors include Dusan Kotasek, Nimit Singhal, Christian Poehlein, Fred Saad, Giuseppe Procopio, Noel W. Clarke, Oliver Sartor, Friederike Schlürmann, Emma Brown and Neal D. Shore and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Francis Parnis
60 papers receiving 758 citations
Hit Papers
Peers
Francis Parnis
Takehiro Okumura Japan
Tyler P. Robin United States
Catherine Park United States
Claudia Valverde Spain
A.H. Honkoop Netherlands
Manabu Yamamoto Japan
John Tsihlias Canada
Franck Priou France
Kuniko Sunami Japan
Giuseppe Comella Italy
Citations per year, relative to Francis Parnis Francis Parnis (= 1×)
peers
Takehiro Okumura
Countries citing papers authored by Francis Parnis
Since
Specialization
Citations
This map shows the geographic impact of Francis Parnis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Parnis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Parnis more than expected).
Fields of papers citing papers by Francis Parnis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Francis Parnis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Parnis. The network helps show where Francis Parnis may publish in the future.
Co-authorship network of co-authors of Francis Parnis
This figure shows the co-authorship network connecting the top 25 collaborators of Francis Parnis. A scholar is included among the top collaborators of Francis Parnis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Parnis. Francis Parnis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079.
2.
Clarke, Noel W., Andrew J. Armstrong, Mototsugu Oya, et al.. (2024). Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. European Urology Oncology. 8(2). 394–406.
3.
Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252.
4.
Horvath, Lisa G., Ian D. Davis, Andrew Martin, et al.. (2023). 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Annals of Oncology. 34. S968–S969.
5.
Lewin, Jeremy, Andrew Weickhardt, James Lynam, et al.. (2023). Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice. 19(11). 973–980.
6.
Saad, Fred, Noel W. Clarke, Mototsugu Oya, et al.. (2023). Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 24(10). 1094–1108.
7.
Pal, Sumanta K., Javier Puente, Daniel Yick Chin Heng, et al.. (2022). Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. European Urology. 82(3). 283–292.
8.
Antón, A., Shirley Wong, Andrew Weickhardt, et al.. (2021). Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. European Journal of Cancer. 157. 485–492.
9.
Richardson, Gary, Francis Parnis, Anis Hamid, et al.. (2021). 137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors. Annals of Oncology. 32. S1436–S1437.
10.
Jensen, Allan, Jeremy Shapiro, Andrew Weickhardt, et al.. (2020). 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1329–S1330.
11.
Powles, Thomas, Evgeny Kopyltsov, Francis Parnis, et al.. (2020). 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Annals of Oncology. 31. S578–S579.
12.
Ryoo, Baek‐Yeol, Philippe Merle, Joong‐Won Park, et al.. (2020). Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 5(4). e000714–e000714.
13.
Shapiro, Jeremy, Andrew Weickhardt, Lavinia Spain, et al.. (2020). 225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort. Annals of Oncology. 31. S1329–S1329.
14.
Parente, Phillip, Francis Parnis, & Howard Gurney. (2012). Emerging and second line therapies for the management of metastatic castration‐resistant prostate cancer: The Australian perspective. Asia-Pacific Journal of Clinical Oncology. 8(1). 31–42.
15.
Khasraw, Mustafa, Nick Pavlakis, Craig Underhill, et al.. (2009). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology. 21(6). 1302–1307.
16.
Borg, Matthew, Eric Yeoh, Melissa Bochner, et al.. (2007). Feasibility study on the MammoSite in early‐stage breast cancer: Initial experience. Australasian Radiology. 51(1). 53–61.
17.
Pittman, Ken, Ian Olver, Bogda Koczwara, et al.. (2006). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. British Journal of Cancer. 95(10). 1309–1313.
18.
Underhill, Craig, Francis Parnis, Martin Highley, et al.. (2001). Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anti-Cancer Drugs. 12(8). 647–652.
19.
Parnis, Francis, Ian Olver, Dusan Kotasek, et al.. (2000). Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Annals of Oncology. 11(7). 883–884.
20.
Parnis, Francis, et al.. (1997). A Phase II Trial of Cisplatin and Interferon Alpha 2b in Patients with Advanced Bladder Cancer. American Journal of Clinical Oncology. 20(3). 319–321.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Takehiro Okumura Breakdown of academic impact, for papers by Tyler P. Robin Breakdown of academic impact, for papers by Catherine Park Breakdown of academic impact, for papers by Claudia Valverde Breakdown of academic impact, for papers by A.H. Honkoop Breakdown of academic impact, for papers by Manabu Yamamoto Breakdown of academic impact, for papers by John Tsihlias Breakdown of academic impact, for papers by Franck Priou Breakdown of academic impact, for papers by Kuniko Sunami Breakdown of academic impact, for papers by Giuseppe Comella